Xtandi®

Active substance Enzalutamide
Holder Astellas Pharma
Status Closed
Indication Asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer in adult patients whose disease progressed during or after androgen deprivation therapy (ADT) but for whom chemotherapy is not yet clinically indicated
Public documents Approbation
Information for the patient
Informed consent
Last update 11/04/2016
Last updated on